Beta-blockers in heart failure. 2. Mode of action

Journal of Clinical Pharmacy and Therapeutics

Volumn 26, Issue 1, 2001, Pages 1-4

  Nuttall, S L ^a   Langford, N J ^a   Kendall, M J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CATECHOLAMINE; ENALAPRIL; METOPROLOL;

ARRHYTHMOGENESIS; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR AUTOREGULATION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; EDITORIAL; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART RATE VARIABILITY; HEMODYNAMICS; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SYMPATHETIC TONE; VAGUS TONE;

ADRENERGIC BETA-ANTAGONISTS; HEART DISEASES; HEART RATE; HUMANS; MYOCARDIUM; OXIDATIVE STRESS;

EID: 0035088126     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2001.00316.x     Document Type: Editorial

References (46)

1. Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials
2. β-blockade after myocardial infarction: Systematic review and meta regression analysis
3. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
4. A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results
5. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
6. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
7. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomised trial
8. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
9. Beta-blockers in heart failure. 1. Clinical evidence
10. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure
11. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
12. Heart rate and cardiovascular mortality: The Framingham study
13. Influence of heart rate on mortality among persons with hypertension: The Framingham study
14. Influence of heart rate on mortality after acute myocardial infarction
15. Heart rate as a therapeutic target in heart failure
16. Timing of sudden death in patients with heart failure
17. Morning peak in the incidence of myocardial infarction: Experience in the ISIS-2 trial
18. Lipid-lowering and plaque regression, new insights into prevention of plaque disruption and clinical events in coronary disease
19. Beneficial effects of vagal stimulation on the ischaemic myocardium during beta-receptor blockade
20. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials
21. Plasma norepinephrine in congestive heart failure
22. Cardiovascular death and left ventricular remodelling two years after myocardial infarction. Baseline predictor and impact of long-term use of captopril: Information from the Survival and Ventricular Enlargement (SAVE) Trial
23. Effect of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
24. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
25. Decreased heart rate variability and its association with increased mortality after myocardial infarction
26. Decreased spontaneous heart rate variability in congestive heart failure
27. Heart rate variability in left ventricular hypertrophy and heart failure, and the effects of beta-blockade
28. Effect of beta-blockade on heart rate variability in patients with coronary artery disease
29. Prognostic value of bisoprolol induced haemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS)
30. Clinical effects of beta adrenergic blockade in chronic heart failure: A meta analysis of double blind, placebo controlled randomised trials
31. Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischaemic heart disease
32. Recovery from left ventricular asynergy in ischaemic cardiomyopathy following long-term beta blockade treatment
33. Impairment of diastolic function by shortened filling period in severe left ventricular disease
34. Medical therapy can improve the biological properties of the chronically failing heart: A new era in the treatment of heart failure
35. A rationale for the use of beta-blockers as standard treatment for heart failure
36. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia
37. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: Relation to pathogenesis of catecholamine cardiomyopathy
38. Cardiovascular injury induced by sympathetic catecholamines
39. Cellular mechanisms in congestive heart failure
40. Effect of metoprolol on myocardial function and energetics in patients with non ischemic dilated cardiomyopathy: A randomiszed, double-blind, placebo controlled study
41. Is the autoxidation of catecholamines involved in ischaemia-reperfusion injury?
42. Evidence of oxidative stress in chronic heart failure in humans
43. Oxidative stress during myocardial ischaemia and heart failure
44. Carvedilol, new beta-adrenoceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction
45. Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension
46. Prospective, randomised comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure